TD Asset Management Inc Sells 30,254 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Key Points

• TD Asset Management Inc reduced its holdings in IDEAYA Biosciences by 46.3%, selling 30,254 shares, and now owns 35,036 shares valued at approximately $574,000.
• Analysts have mixed ratings for IDEAYA Biosciences, with 10 buy ratings against 3 hold ratings, while the average target price sits at $48.09.
• IDEAYA reported a quarterly EPS of ($0.82), missing expectations by $0.07, compared to a loss of ($0.53) per share in the same quarter last year.

TD Asset Management Inc trimmed its holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 46.3% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 35,036 shares of the company's stock after selling 30,254 shares during the period. TD Asset Management Inc's holdings in IDEAYA Biosciences were worth $574,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently made changes to their positions in IDYA. CWM LLC lifted its stake in shares of IDEAYA Biosciences by 325.7% in the first quarter. CWM LLC now owns 2,371 shares of the company's stock valued at $39,000 after buying an additional 1,814 shares in the last quarter. GF Fund Management CO. LTD. bought a new position in shares of IDEAYA Biosciences in the fourth quarter valued at $47,000. Signaturefd LLC lifted its stake in shares of IDEAYA Biosciences by 374.8% in the first quarter. Signaturefd LLC now owns 2,877 shares of the company's stock valued at $47,000 after buying an additional 2,271 shares in the last quarter. Exchange Traded Concepts LLC lifted its stake in shares of IDEAYA Biosciences by 46.4% in the first quarter. Exchange Traded Concepts LLC now owns 6,659 shares of the company's stock valued at $109,000 after buying an additional 2,112 shares in the last quarter. Finally, Oppenheimer Asset Management Inc. lifted its stake in shares of IDEAYA Biosciences by 33.2% in the first quarter. Oppenheimer Asset Management Inc. now owns 11,560 shares of the company's stock valued at $189,000 after buying an additional 2,884 shares in the last quarter. 98.29% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts have recently commented on the stock. TD Cowen assumed coverage on shares of IDEAYA Biosciences in a report on Tuesday, July 22nd. They issued a "buy" rating for the company. JPMorgan Chase & Co. increased their target price on shares of IDEAYA Biosciences from $66.00 to $72.00 and gave the company an "overweight" rating in a report on Monday, July 28th. Royal Bank Of Canada upgraded shares of IDEAYA Biosciences from an "outperform" rating to a "moderate buy" rating and lowered their target price for the company from $57.00 to $30.00 in a report on Wednesday, July 9th. Wells Fargo & Company assumed coverage on shares of IDEAYA Biosciences in a report on Thursday, June 26th. They issued an "overweight" rating and a $44.00 target price for the company. Finally, The Goldman Sachs Group upgraded shares of IDEAYA Biosciences to a "hold" rating and set a $25.00 target price for the company in a report on Thursday, July 10th. Three research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $48.09.

IDEAYA Biosciences Stock Performance

NASDAQ IDYA opened at $25.00 on Tuesday. IDEAYA Biosciences, Inc. has a 52-week low of $13.45 and a 52-week high of $40.74. The company has a 50-day simple moving average of $22.19 and a 200 day simple moving average of $20.33. The company has a market capitalization of $2.19 billion, a PE ratio of -6.96 and a beta of 0.09.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The company reported ($0.82) EPS for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.07). During the same quarter in the previous year, the firm earned ($0.53) earnings per share. As a group, analysts forecast that IDEAYA Biosciences, Inc. will post -3.07 EPS for the current fiscal year.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.

Want to see what other hedge funds are holding IDYA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.